Liver Diseases  >>  MK-2206  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-2206 / Merck (MSD)
NCT01239355: MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Terminated
2
15
US
Akt Inhibitor MK2206, MK2206, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
02/13
02/13

Download Options